Immunotherapies with monoclonal antibody and anti-TNF-α agents, certolizumab pegol and adalimumab, significantly improved clinical symptoms in IC/BPS women through the inhibition of mast cell degranulation [86], highlighting that TNF-α might represent a crucial therapeutic target for IC/BPS. Here, TNF is linked to Bartsocas-Papas syndrome 1.